Skip to main content
TrimSoMoEverything GLP-1, in one place
  1. Preclinical
  2. Phase 1
  3. Phase 2
  4. Phase 3
  5. FDA review
  6. FDA decision
Generic stages for illustration; not the status of any listed drug.

Stages show where a medicine is in development, not whether it is approved or available. Not a recommendation.

Pipeline status & sources

GLP-1 Pipeline:
Development Stage & Sources

FDA-approved oral products and candidates still in development, with label or public sources for each.

FDA-approved oral GLP-1 medications

Foundayo (orforglipron)

Eli Lilly and Company. FDA approval: April 1, 2026.

FDA-approved use (from the FDA announcement): Foundayo is approved for use in combination with a reduced-calorie diet and increased physical activity to reduce excess body weight and maintain weight reduction long term in adults with obesity or adults with overweight in the presence of at least one weight-related comorbid condition.

Foundayo's FDA labeling includes a boxed warning. Read the full prescribing information before making any decision.

Checked November 4, 2026. Read the FDA label and talk with a clinician for details.

Wegovy tablets (oral semaglutide)

Novo Nordisk.

Strengths (from the prescribing information): 1.5 mg, 4 mg, 9 mg, and 25 mg tablets

Labeled uses (summary from the prescribing information): Indicated in combination with a reduced-calorie diet and increased physical activity to reduce the risk of major adverse cardiovascular events in adults with established cardiovascular disease and either obesity or overweight, and to reduce excess body weight and maintain weight reduction long term in adults with obesity or adults with overweight in the presence of at least one weight-related comorbid condition.

Checked November 4, 2026. Read the FDA label and talk with a clinician for details.

In development

Investigational, not FDA‑approved. Entries in this section are investigational. This section describes only development stage and public sources; it makes no claims about safety, effectiveness or cost. Status checked November 4, 2026.

Scroll pipeline matrix horizontallySwipe →
Drug NameDeveloperTarget MechanismRouteClinical StatusSponsor-Stated Timing
Amycretin (zenagamtide)NNC0487-0111Novo NordiskGLP-1 & amylin receptor agonist (single molecule)Oral & SubcutaneousPhase 3Registry-listed completion dates for these trials are 2028–2029. No FDA application has been announced.
VK2735VK2735Viking TherapeuticsDual GLP-1 & GIP Receptor AgonistOral & SubcutaneousPhase 3Registry-estimated completion: VANQUISH 1, August 2027; SUNRISE 1, August 2028. No FDA application has been announced.
CagriSemaSemaglutide + CagrilintideNovo NordiskGLP-1 RA + Long-Acting Amylin AnalogSubcutaneous InjectionPre-RegistrationNDA submitted December 2025 (per Novo Nordisk). No FDA decision has been announced.

Amycretin (zenagamtide)

Phase 3Route: Oral & Subcutaneous

NNC0487-0111 • Novo Nordisk

GLP-1 & amylin receptor agonist (single molecule)

Amycretin is an investigational molecule from Novo Nordisk that acts on GLP-1 and amylin receptors. It is being studied in Phase 3 trials for weight management in adults with overweight or obesity.

Trials & Regulatory Status

AMAZE Phase 3 program (e.g. AMAZE 1, NCT07339423; AMAZE 9, NCT07720271)

Investigational, not FDA-approved. Safety and efficacy have not been established by FDA review.

Sponsor-Stated Timing

Registry-listed completion dates for these trials are 2028–2029. No FDA application has been announced.

Development notes

  • ClinicalTrials.gov lists Phase 3 AMAZE 1 (NCT07339423, start date February 24, 2026) and AMAZE 9 (NCT07720271, tablet, start date August 31, 2026), both recruiting.
  • Development stage only; no FDA application has been announced.

Sources: Novo Nordisk announcement (zenagamtide, also known as amycretin), June 5, 2026 · ClinicalTrials.gov — AMAZE 9 (NCT07720271) · ClinicalTrials.gov — AMAZE 1 (NCT07339423)

As of November 4, 2026

VK2735

Phase 3Route: Oral & Subcutaneous

VK2735 • Viking Therapeutics

Dual GLP-1 & GIP Receptor Agonist

VK2735 is an investigational dual GLP-1 and GIP receptor agonist from Viking Therapeutics, studied as a weekly injection and as a daily tablet.

Trials & Regulatory Status

VANQUISH 1 (NCT07104500) and VANQUISH 2 (NCT07104383) (injection); SUNRISE 1 (NCT07868835) and SUNRISE 2 (NCT07868939) (tablet)

Investigational, not FDA-approved. Safety and efficacy have not been established by FDA review.

Sponsor-Stated Timing

Registry-estimated completion: VANQUISH 1, August 2027; SUNRISE 1, August 2028. No FDA application has been announced.

Development notes

  • ClinicalTrials.gov lists Phase 3 VANQUISH 1 (NCT07104500, weekly injection) as active, not recruiting, with an estimated completion date of August 2027.
  • Viking reported on October 28, 2026 that SUNRISE Phase 3 trials of the tablet were initiated; ClinicalTrials.gov lists SUNRISE 1 (NCT07868835) as not yet recruiting.

Sources: ClinicalTrials.gov — VANQUISH 1 (NCT07104500) · ClinicalTrials.gov — VANQUISH 2 (NCT07104383) · ClinicalTrials.gov — SUNRISE 1 (NCT07868835) · ClinicalTrials.gov — SUNRISE 2 (NCT07868939) · Viking Therapeutics Q3 2026 corporate update, October 28, 2026

As of November 4, 2026

CagriSema

Pre-RegistrationRoute: Subcutaneous Injection

Semaglutide + Cagrilintide • Novo Nordisk

GLP-1 RA + Long-Acting Amylin Analog

CagriSema is an investigational once-weekly injection that combines semaglutide with cagrilintide, an amylin analogue. Novo Nordisk has submitted a New Drug Application to the FDA; no FDA decision has been announced.

Trials & Regulatory Status

REDEFINE Phase 3 program (REDEFINE 1 & 2)

Investigational, not FDA-approved. Novo Nordisk's December 18, 2025 announcement states that CagriSema is not approved in the US or EU.

Sponsor-Stated Timing

NDA submitted December 2025 (per Novo Nordisk). No FDA decision has been announced.

Development notes

  • Novo Nordisk announced on December 18, 2025 that it submitted a New Drug Application to the FDA, based on the REDEFINE 1 and 2 trials.
  • The FDA has not announced a decision. Novo Nordisk's November 4, 2026 report describes CagriSema as subject to regulatory approval.

Sources: Novo Nordisk NDA submission announcement, December 18, 2025 · Novo Nordisk company announcement, 9M/Q3 2026 results, November 4, 2026 · ClinicalTrials.gov — CagriSema studies

As of November 4, 2026

Current Access Options

Looking for currently approved options?

Investigational medicines are not FDA-approved. Read about currently approved GLP-1 medications and telehealth programs, and talk with a licensed clinician about what is right for you.